AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$SIBN

DUNN JEFFREY W sold $378K of SIBN

DUNN JEFFREY W sold 20,000 shares of SI-BONE, Inc. (SIBN) at $18.91 ($0.38M total) across 2 trades on 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · DUNN JEFFREY W
Published Sep 3, 2026, 11:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 11:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SIBN
Bearish
medium confidence
Mentioned
$SIBN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SIBNBearishLow
01

Why it matters

The disclosed sale adds a data point for investors monitoring insider sentiment.

02

Market read

A modest insider sale; limited immediate market impact but useful for sentiment tracking.

03

What to watch

The director retains 16,057 shares, indicating continued confidence; overall insider ownership remains sizable.

Relevance 3/10Novelty 5/10Timing: filed 2026-09-03, effective immediately

Background

Form 4 filings disclose insider transactions; a 10b5-1 plan allows pre‑scheduled sales.

Company-level read

Ticker impact

$SIBNBearishMedium confidence
Context

Director Jeffrey Dunn sold 20,000 shares for $378,160 via a 10b5-1 plan on 2026-09-01.

Expected impact

Possible modest downside of 1‑2% in the near term.

Evidence & confidence

Sale size is modest relative to market cap, but insider disposition is a bearish indicator.

Market effects

Sector

Minimal; limited impact on the broader orthopedic device sector.

Regional

None; the filing is company‑specific.

Global

Low; no broader market effect.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing under a pre‑arranged plan, not a negative signal.

Key entities

  • Director
    Jeffrey Dunn

    Director of SI‑BONE, Inc. who executed the sale.

  • Company
    SI‑BONE, Inc.

    Medical device company specializing in orthopedic implants.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SIBN insider trading history →

Related articles

$SIBNHigh

Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%

Healthcare stocks rose due to earnings reports and corporate actions. SI-BONE (SIBN) reported Q3 revenue of $55.7M, a 14.5% increase, and reaffirmed its full-year outlook. Neurocrine Biosciences (NBIX) reported Q3 revenue of $1.122B, up 41.1%. Rockwell Medical (RMTI) agreed to acquire Vantive's hemodialysis assets. PTC Therapeutics (PTCT) authorized a $500M share repurchase program.

rttnews.com
$SIBNMed

SI-BONE (SIBN) Q3 2026 Earnings Call Transcript

SI-BONE (SIBN) reported Q3 2026 earnings, highlighting 27% international revenue growth and 32% adjusted EBITDA increase. The company launched iFuse Granite Onyx, expanding its market to 650,000 procedures and $5B opportunity. Onyx targets spinal fusion failure points, with early demand exceeding expectations. New DRGs and reimbursement enhancements support growth. The company expects 20%+ revenue growth in Q4 2026.

finance.yahoo.com
$SIBNMed

SiBone Q3 Earnings Call Highlights

SiBone (SIBN) reported Q3 earnings, highlighting strong demand for its Onyx platform, which targets a $1.5B market. Gross profit rose 13.7% to $44.2M, with gross margin at 79.3%. Net loss narrowed to $3.6M. The company reaffirmed 2026 revenue guidance of $231M-$233M and expects Q4 momentum from physician growth and new products.

finance.yahoo.com